MHRA Data_integrity_definitions_and_guidance_v2 (1)
- 格式:pdf
- 大小:236.86 KB
- 文档页数:16
201501 MHRA数据完整性指南2015-01-2921:33:23| 分类:EDQM | 标签:|举报|字号大中小订阅MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015MHRA的GMP数据完整性定义和行业指南/2015年1月Introduction:背景介绍Dataintegrity is fundamental in a pharmaceutical quality system which ensures thatmedicines are of the required quality. This document provides MHRA guidance onGMP data integrity expectations for the pharmaceutical industry. This guidanceis intended to complement existing EU GMP, and shouldbe read in conjunctionwith national medicines legislation and the GMP standards published in Eudralexvolume 4.数据完整性在药品质量体系中是基本要求,它保证药品具有所需要的质量。
本文件向制药行业提供MHRA关于GMP数据完整性方面期望的指南。
本指南意在对现有EUGMP进行补充,应与国家药监法规和欧洲法规第4卷的GMP标准联合解读。
The datagovernance system should be integral to the pharmaceutical quality systemdescribed in EU GMP chapter 1. The effort and resource assigned to datagovernance should be commensurate with the risk to product quality, and shouldalso be balanced with other quality assurance resource demands. As such,manufacturers and analytical laboratories are not expected to implement aforensic approach to data checking, but instead design and operate a systemwhich provides an acceptable state of control based on the data integrity risk,and which is fully documented with supporting rationale.数据管理系统应与EU GMP第1章中描述的药品质量体系相结合。
MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015MHRA GMP 数据完整性定义和行业指导原则2015年3月简述:Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This document provides MHRA guidance on GMP data integrity expectations for the pharmaceutical industry. This guidance isintended to complement existing EU GMP relating to active substances and dosage forms, and should be read in conjunction with national medicines legislation and the GMP standards published in Eudralex volume 4.数据完整性是制药质量体系确保药品质量的基石。
本文提供了MHRA对制药行业GMP数据完整性方面的指导原则。
本指导原则旨在对现有欧盟有关原料药和药物制剂的GMP进行补充说明,需结合国家药品法规及颁布在Eudralex 第四册内的GMP标准进行阅读理解。
The data governance system should be integral to the pharmaceutical quality system described in EU GMP chapter 1. The effort and resource assigned to data governance should be commensurate with the risk to product quality, and should also be balanced with otherquality assurance resource demands. As such, manufacturers and analytical laboratories arenot expected to implement a forensic approach to data checking on a routine basis, butinstead design and operate a system which provides an acceptable state of control based onthe data integrity risk, and which is fully documented with supporting rationale.数据管理体系应该与欧盟EU GMP第一章所述的质量体系结合在一起。
记录/台账类电子表格的数据完整性要求MS Excel is used in analytical laboratories for many purposes - for example for calculations, and frequently also for the storage of data. For electronically stored data, there have been requirements since the formation of the EU GMP Guide. They are defined in Chapter 4 (Documentation) and in the complementary Guideline (Annex 11), which both have been revised a few years ago. This year (in March 2015), the British MHRA has summarised and interpreted the existing GMP requirements for data security in a new guideline ("MHRA GMP Data Integrity Definitions and Guidance for Industry"). Please also see the GMP news from February 2015 with regard to the new MHRA Guideline and from April 2015 relative to the short-term revision of the MHRA Guideline for data integrity.MS EXCEL在化验室有很多用途---例如,用于计算,还常用于数据存贮。
DataIntegrityViolationException是一个数据库异常,通常在执行数据库操作时遇到数据完整性约束的冲突时抛出。
这种异常表示一项操作违反了数据库表的约束条件,例如唯一性约束、主键约束或外键约束等。
解决DataIntegrityViolationException的方法取决于具体的情况。
以下是一些可能的解决方法:1. 检查数据:首先,检查要插入、更新或删除的数据是否满足表的约束条件。
确保没有重复的值、缺少必需的值或其他违反约束的情况。
2. 处理冲突:如果发生冲突,可以通过合适的方式处理。
例如,对于唯一性冲突,可以选择更新现有记录或者忽略冲突的操作。
3. 使用事务:将相关操作放在事务中可以确保数据的一致性和完整性。
如果某个操作失败,可以回滚整个事务,以避免部分操作导致数据不一致。
4. 检查外键关系:当涉及到外键约束时,确保引用的外键存在于关联表中。
如果引用的外键不存在,插入或更新会导致DataIntegrityViolationException。
5. 日志记录和错误处理:对于发生的DataIntegrityViolationException异常,应该记录日志并进行适当的错误处理。
这样可以帮助识别和修复引起异常的问题。
6. 数据库优化:有时,DataIntegrityViolationException可能是由于数据库性能或配置问题导致的。
可以考虑对数据库进行优化,例如增加索引、优化查询语句等。
总的来说,解决DataIntegrityViolationException需要仔细检查数据、处理冲突、使用事务等方法来确保数据的完整性和一致性。
如果问题持续存在,可能需要进一步分析和调试。
在数据完整性的"真实副本“方面,涉及的相关的法规要求如下:
药品记录与数据管理要求(试行)第十八条记录的使用与复制应当采取适当措施防止记录的丢失、损坏或篡改。
复制记录时,应当规定记录复制的批准、分发、控制方法,明确区分记录原件与复印件。
MHRA GXP Data
Integrity Guidanceand Definitions; Revision 1: March 20186.11.2 True Copy 必要时,真实副本可以不同于原始记录的电子文件格式存贮,但必须保存必要的元数据和审计追踪以确保数据的全部含义得到保存,且可以重构其历史。
应有可能创建一份电子数据的真实副本,包括相关的原数据,用于审核、备份和归档。
完整准确的副本应包括数据的含义(例如,日期格式、环境、布局、电子签名和授权)和全面的GXP审计追踪。
应考虑整个保留时期内“真实副本”的动态功能。
原始记录的认证真实副本可代替原始记录保留,仅当副本已与原始记录相比对而且确认其包含原始记录的全部内容和含义。
除选择创建原始电
子数据认证真实副本作为确认的备份副本然后安全地电子归档外,创建原始电子数据的认证真实副本的另一个选择是,将原始电子数据从一个系统转移到其他系统,并确认和记录经验证的数据转移过程可保存全部的内容,包括全部有意义的元数据以及原始电子数据的含义。
缺陷示例:
•保存在硬盘中的重要原始文件,如采集或扫描的图谱文件、进样序列文件等的删除、复制、剪切等不受控,属于恶意删除关键数据的;(严重缺陷)
•复制后的副本不能在同一系统上重新读取;
•副本不受保护,可以随意删除或更改;
•缺乏充分的第二人复核以确认打印数据为原始电子数据的真实副本。
MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015Introduction:Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This document provides MHRA guidance on GMP data integrity expectations for the pharmaceutical industry. This guidance is intended to complement existing EU GMP relating to active substances and dosage forms, and should be read in conjunction with national medicines legislation and the GMP standards published in Eudralex volume 4.The data governance system should be integral to the pharmaceutical quality system described in EU GMP chapter 1. The effort and resource assigned to data governance should be commensurate with the risk to product quality, and should also be balanced with other quality assurance resource demands. As such, manufacturers and analytical laboratories are not expected to implement a forensic approach to data checking on a routine basis, but instead design and operate a system which provides an acceptable state of control based on the data integrity risk, and which is fully documented with supporting rationale.Data integrity requirements apply equally to manual (paper) and electronic data. Manufacturers and analytical laboratories should be aware that reverting from automated / computerised to manual / paper-based systems will not in itself remove the need for data integrity controls. This may also constitute a failure to comply with Article 23 of Directive 2001/83/EC, which requires an authorisation holder to take account of scientific and technical progress and enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods.Throughout this guidance, associated definitions are shown as hyperlinks.Establishing data criticality and inherent integrity risk:In addition to an overarching data governance system, which should include relevant policies and staff training in the importance of data integrity, consideration should be given to the organisational (e.g. procedures) and technical (e.g. computer system access) controls applied to different areas of the quality system. The degree of effort and resource applied to the organisational and technical control of data lifecycle elements should be commensurate with its criticality in terms of impact to product quality attributes.Data may be generated by (i) a paper-based record of a manual observation, or (ii) in terms of equipment, a spectrum of simple machines through to complex highly configurable computerised systems. The inherent risks to data integrity may differ depending upon the degree to which data (or the system generating or using the data) can be configured, and therefore potentially manipulated (see figure 1).Figure 1: Diagram to illustrate the spectrum of simple machine (left) to complex computerised system (right), and relevance of printouts as ‘original data’(diagram acknowledgement: Green Mountain QA LLC) With reference to figure 1 above, simple systems (such as pH meters and balances) may only require calibration, whereas complex systems require ‘validation for intended purpose’. Validation effort increases from left to right in the diagram above. However, it is common for companies to overlook systems of apparent lower complexity. Within these systems it may be possible to manipulate dataor repeat testing to achieve a desired outcome with limited opportunity of detection (e.g. stand-alone systems with a user configurable output such as FT-IR, UV spectrophotometers).Designing systems to assure data quality and integritySystems should be designed in a way that encourages compliance with the principles of data integrity. Examples include:•Access to clocks for recording timed events•Accessibility of batch records at locations where activities take place so that ad hoc data recording and later transcription to official records is not necessary•Control over blank paper templates for data recording•User access rights which prevent (or audit trail) data amendments•Automated data capture or printers attached to equipment such as balances•Proximity of printers to relevant activities•Access to sampling points (e.g. for water systems)•Access to raw data for staff performing data checking activities.The use of scribes to record activity on behalf of another operator should be considered ‘exceptional’, and only take place where:•The act of recording places the product or activity at risk e.g. documenting line interventions by sterile operators.•To accommodate cultural or staff literacy / language limitations, for instance where an activity is performed by an operator, but witnessed and recorded by a Supervisor or Officer.In both situations, the supervisory recording must be contemporaneous with the task being performed, and must identify both the person performing the observed task and the person completing the record. The person performing the observed task should countersign the record wherever possible, although it is accepted that this countersigning step will be retrospective. The process for supervisory (scribe) documentation completion should be described in an approved procedure, which should also specify the activities to which the process applies.In the following definitions, the term 'data' includes raw data.Term Definition Expectation / guidance (where relevant)Data Information derived or obtained from raw data (e.g. areported analytical result)Data must be:A - attributable to the person generating the dataL – legible and permanentC – contemporaneousO – original record (or ‘true copy’)A - accurateRaw data Original records and documentation, retained in the formatin which they were originally generated (i.e. paper orelectronic), or as a ‘true copy’. Raw data must becontemporaneously and accurately recorded by permanentmeans. In the case of basic electronic equipment whichdoes not store electronic data, or provides only a printeddata output (e.g. balance or pH meter), the printoutconstitutes the raw data.Raw data must:•Be legible and accessible throughout the data lifecycle.•Permit the full reconstruction of the activities resulting in thegeneration of the dataFigure 2: Logical design permitting contemporaneous recording of addition of asingle material in a manufacturing ‘unit of work’. This record is permanentlyrecorded (step 2), with audit trail, before progressing to next ‘unit of work’.Figure 3: Logical design permitting the addition of multiple materials in a manufacturing‘unit of work’ before committing the record to durable media. Steps 1, 3 and 5 arecontemporaneous entries (bar code), but are not permanently recorded with audit trail untilstep 6.Revision History。